Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Former Mylan executive pleads guilty to insider trading

Published 09/17/2021, 05:32 PM
Updated 09/17/2021, 05:38 PM
© Reuters. FILE PHOTO: Logo of Mylan Laboratories, a company primarily engaged in the commercialization of generic drugs is pictured in Merignac near Bordeaux, France, September 19, 2019. REUTERS/Regis Duvignau

By Jonathan Stempel and Chris Prentice

(Reuters) - A former information technology executive at Mylan (NASDAQ:VTRS) pleaded guilty on Friday to insider trading for using tips from the drugmaker's chief information officer to trade in its stock, generating $4.27 million of illegal profit, authorities said.

Dayakar Mallu, 51, admitted to conspiring to commit securities fraud, and to an unrelated charge of helping prepare a false tax return, before U.S. District Judge W. Scott Hardy in Pittsburgh.

Mylan is now known as Viatris Inc after merging last November with Pfizer Inc (NYSE:PFE)'s Upjohn off-patent drug business, which Pfizer spun off. The combined company's headquarters remain in Canonsburg, Pennsylvania, a Pittsburgh suburb.

Authorities said that between October 2017 and July 2019, Mallu traded Mylan stock based on material nonpublic information about the company's results, U.S. Food and Drug Administration drug approvals, and the Upjohn merger.

Mallu, now a resident of Orlando, Florida, was previously vice president of global operations information technology at Mylan, and had been a friend and colleague of the chief information officer, court records show.

The tax return charge related to a computer programming company based in Farmington Hills, Michigan, that Mallu owned, prosecutors said.

Mallu could face 57 to 71 months in prison under recommended federal guidelines at his Jan. 24, 2022, sentencing, according to a plea agreement with the U.S. Department of Justice.

He also agreed to forfeit $4.27 million and make restitution to the Internal Revenue Service, court records show. The U.S. Securities and Exchange Commission filed related civil charges.

Aitan Goelman, a lawyer for Mallu, declined to comment.

Ramkumar Rayapureddy, who was Mylan's CIO at the time of Mallu's trading, now holds the same job at Viatris, according to Viatris' website and his LinkedIn Page.

The SEC said Mallu shared some profits with the source of his inside information, who directed him to make cash payments in person, in India, to avoid detection.

© Reuters. FILE PHOTO: Logo of Mylan Laboratories, a company primarily engaged in the commercialization of generic drugs is pictured in Merignac near Bordeaux, France, September 19, 2019. REUTERS/Regis Duvignau

Rayapureddy did not immediately respond to a request for comment.

In a statement, Viatris said: "The company is committed to the highest standards of integrity and compliance with the law. The company has been fully cooperating with the authorities. We are not in a position to comment further."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.